SOURCE: OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals, Inc.

May 24, 2016 08:00 ET

OncBioMune Receives Patent on Paclitaxel-Gallium-Transferrin for Targeted Cancer Treatment

BATON ROUGE, LA--(Marketwired - May 24, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce that it has been granted US Patent # 9,333,189 B2 on May 10, 2016 from the U.S. Patent and Trademark Office (USPTO), titled "Taxane-and taxoid-protein compositions."

The patent protects OncBioMune's novel transferring transport technology, which overcomes shortfalls in current approved taxane therapies for an array of cancers, such as paclitaxel and docetaxel. While effective and commonly used, these therapies are limited because of inefficient delivery of the drug to the tumor cell and non-specific toxicity towards healthy cells, which can cause complications ranging from inflammation to death of the patient.

The patent protects the Company's novel transferrin transport technology, an innovative approach to chemotherapy to better target tumor cells and reduce toxicity to healthy cells. Specifically, claims in the patent cover novel compositions comprising the protein transferrin, and a taxane or taxoid, which does not utilize a linking group between the taxane and protein. The claims cover drug development utilizing the technology for a broad spectrum of cancers, including, but not limited to sarcoma, lymphoma, leukemia, prostate, lung and breast.

A continuance of the original US patent application #13/017,173 is being pursued to also patent a paclitaxel-albumin drug which is similar to Celegene's Abraxane.

"As we prepare to enter the two, separate Phase 2 trials of ProscaVax, our lead prostate cancer vaccine, we are busy in the lab working towards development of our transferrin and albumin transport technologies," said Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "We believe that our paclitaxel-gallium-transferrin composition represents a major improvement that can substantially reduce toxicity issues and improve clinical outcomes in the taxane family of drugs that are commonly prescribed today. In addition, our albumin-paclitaxel will be competitive with similar combinations of albumin and paclitaxel."

Sign up for OncBioMune email alerts at:

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax™ is scheduled to commence a Phase 2 clinical study in early 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceutical's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Contact Information


    OncBioMune Pharmaceuticals, Inc.
    Andrew Kucharchuk
    President and Chief Financial Officer